Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives

被引:53
作者
Nappi, Anna [1 ]
Berretta, Massimiliano [2 ,3 ]
Romano, Carmela [1 ]
Tafuto, Salvatore [1 ]
Cassata, Antonino [1 ]
Casaretti, Rossana [1 ]
Silvestro, Lucrezia [1 ]
De Divitiis, Chiara [1 ]
Alessandrini, Lara [4 ]
Fiorica, Francesco [5 ]
Ottaiano, Alessandro [1 ]
Nasti, Guglielmo [1 ]
机构
[1] Natl Canc Inst G Pascale Fdn, Abdominal Dept, Med Oncol, I-80131 Naples, Italy
[2] Natl Canc Inst Aviano, Dept Med Oncol, I-33081 Aviano, PN, Italy
[3] Grp Oncol Ricercatori Italiani, Pordenone, PN, Italy
[4] Natl Canc Inst, Div Pathol, Aviano, PN, Italy
[5] St Anna Hosp, Div Radiotherapy, Ferrara, Italy
关键词
Colorectal cancer; monoclonal antibodies; target therapy; treatment; anti-VEGF drugs; anti-EGFR; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; OXALIPLATIN-BASED CHEMOTHERAPY; CETUXIMAB PLUS IRINOTECAN; WILD-TYPE KRAS; 1ST-LINE TREATMENT; PANITUMUMAB PLUS; ELDERLY-PATIENTS; OLDER PATIENTS; OPEN-LABEL;
D O I
10.2174/1568009617666170209095143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts. Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up-regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-Ll agents has led to remarkable clinical responses in patients affected by many different types of cancer. The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC. We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 68 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]  
[Anonymous], 2014, WCRJ
[3]   Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials [J].
Aprile, Giuseppe ;
Fontanella, Caterina ;
Bonotto, Marta ;
Rihawi, Karim ;
Lutrino, Stefania Eufemia ;
Ferrari, Laura ;
Casagrande, Mariaelena ;
Ongaro, Elena ;
Berretta, Massimiliano ;
Avallone, Antonio ;
Rosati, Gerardo ;
Giuliani, Francesco ;
Fasola, Gianpiero .
ONCOTARGET, 2015, 6 (30) :28716-28730
[4]  
Arnold D, 2012, J CLIN ONCOL S, V30
[5]   Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer [J].
Asghar, Uzma ;
Hawkes, Eliza ;
Cunningham, David .
CLINICAL COLORECTAL CANCER, 2010, 9 (05) :274-281
[6]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[7]   Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC) [J].
Berretta, Massimiliano ;
Zanet, Ernesto ;
Nasti, Guglielmo ;
Lleshi, Arben ;
Frustaci, Sergio ;
Fiorica, Francesco ;
Bearz, Alessandra ;
Talamini, Renato ;
Lestuzzi, Chiara ;
Lazzarini, Renzo ;
Fisichella, Rossella ;
Cannizzaro, Renato ;
Iaffaioli, Rosario Vincenzo ;
Berretta, Salvatore ;
Tirelli, Umberto .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2012, 55 (02) :271-275
[8]   FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study [J].
Berretta, Massimiliano ;
Cappellani, Alessandro ;
Fiorica, Francesco ;
Nasti, Guglielmo ;
Frustaci, Sergio ;
Fisichella, Rossella ;
Bearz, Alessandra ;
Talamini, Renato ;
Lleshi, Arben ;
Tambaro, Rosa ;
Cocciolo, Alessandro ;
Ristagno, Maurizio ;
Bolognese, Antonio ;
Basile, Francesco ;
Meneguzzo, Nereo ;
Berretta, Salvatore ;
Tirelli, Umberto .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2011, 52 (01) :89-93
[9]  
Bokemeyer C., 2010, ASCO GI C
[10]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671